Abstract
Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS+); 6 without CNS metastasis (CNS−)], 21 with carcinomas (10 CNS+; 11 CNS−), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS+ lymphoma group were significantly higher than in the CNS− lymphoma and control non-cancer groups; and were also significantly higher in the CNS+ carcinoma group than in the CNS− carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS+ lymphoma from CNS− lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS+ carcinomas from CNS− carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS+ lymphoma and carcinomas compared to corresponding CNS− diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS+ lymphoma and metastasis.
Similar content being viewed by others
References
Lee W, Kim SJ, Lee S et al (2005) Significance of cerebrospinal fluid sIL-2R level as a marker of CNS involvement in acute lymphoblastic leukemia. Ann Clin Lab Sci 35:407–412
Hansen PB, Kjeldsen L, Dalhoff K, Olesen B (1992) Cerebrospinal fluid beta-2-microglobulin in adult patients with acute leukemia or lymphoma: a useful marker in early diagnosis and monitoring of CNS-involvement. Acta Neurol Scand 85:224–227
Aviles A, Gómez R, Salas J (1991) Ferritin in the cerebrospinal fluid as an early indicator of neuromeningeal involvement in patients with malignant lymphoma. Gac Med Mex 127:249–252 (Spanish)
Roy S, Josephson SA, Fridlyand J et al (2008) Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 26:96–105
Baraniskin A, Kuhnhenn J, Schlegel U et al (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117:3140–3146
Wei D, Wan Q, Li L et al (2015) MicroRNAs as potential biomarkers for diagnosing cancers of central nervous system: a meta-analysis. Mol Neurobiol 51:1452–1461
Yu X, Li Z, Shen J, Chan MT, Wu WK (2016) Role of microRNAs in primary central nervous system lymphomas. Cell Prolif 49:147–153
Viaccoz A, Ducray F, Tholance Y et al (2015) CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. Neuro Oncol 17:1497–1503
Strehlow F, Bauer S, Martus P et al (2016) Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. J Neurooncol 129:165–171
Rubenstein JL, Wong VS, Kadoch C et al (2013) CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 121:4740–4748
Fischer L, Korfel A, Pfeiffer S et al (2009) CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 15:5968–5973
Berghoff AS, Stefanits H, Woehrer A et al (2013) Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin Neuropathol 32:148–158
Ahluwalia MS, Wallace PK, Peereboom DM (2012) Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis: ready for prime time? Cancer 118:1747–1753
He Z, Bateman A (1999) Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res 59:3222–3229
He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A (2002) Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res 62:5590–5596
He Z, Bateman A (2003) Progranulin (granulin–epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 81:600–612
Serrero G (2003) Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis. Biochem Biophys Res Commun 308:409–413
Ong CH, Bateman A (2003) Progranulin (granulin–epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histol Histopathol 18:1275–1288
Serrero G, Ioffe OB (2003) Expression of PC-cell-derived growth factor in benign and malignant human breast epithelium. Hum Pathol 34:1148–1154
Ho JC, Ip YC, Cheung ST et al (2008) Granulin–epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology 47:1524–1532
Cuevas-Antonio R, Cancino C, Arechavaleta-Velasco F et al (2010) Expression of progranulin (acrogranin/PCDGF/granulin–epithelin precursor) in benign and malignant ovarian tumors and activation of MAPK signaling in ovarian cancer cell line. Cancer Invest 28:452–458
Dong T, Yang D, Li R et al (2016) PGRN promotes migration and invasion of epithelial ovarian cancer cells through an epithelial mesenchymal transition program and the activation of cancer associated fibroblasts. Exp Mol Pathol 100:17–25
Tangkeangsirisin W, Hayashi J, Serrero G (2004) PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res 64:1737–1743
Tangkeangsirisin W, Serrero G (2004) PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 25:1587–1592
Matsumura N, Mandai M, Miyanishi M et al (2006) Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis. Clin Cancer Res 12:1402–1411
Frampton G, Invernizzi P, Bernuzzi F et al (2012) Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 61:268–277
Frampton G, Ueno Y, Quinn M et al (2012) The novel growth factor, progranulin, stimulates mouse cholangiocyte proliferation via sirtuin-1-mediated inactivation of FOXO1. Am J Physiol Gastrointest Liver Physiol 303:G1202–G1211
Göbel M, Eisele L, Möllmann M et al (2013) Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. PLoS ONE 8:e72107
Edelman MJ, Feliciano J, Yue B et al (2014) GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma. Hum Pathol 45:1893–1899
Monami G, Gonzalez EM, Hellman M et al (2006) Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res 66:7103–7110
Wang M, Li G, Yin J, Lin T, Zhang J (2012) Progranulin overexpression predicts overall survival in patients with glioblastoma. Med Oncol 29:2423–2431
Lu Y, Zheng L, Zhang W et al (2014) Growth factor progranulin contributes to cervical cancer cell proliferation and transformation in vivo and in vitro. Gynecol Oncol 134:364–371
Wei Z, Huang Y, Xie N, Ma Q (2015) Elevated expression of secreted autocrine growth factor progranulin increases cervical cancer growth. Cell Biochem Biophys 71:189–193
Demorrow S (2013) Progranulin: a novel regulator of gastrointestinal cancer progression. Transl Gastrointest Cancer 2:145–151
Yang D, Wang LL, Dong TT et al (2015) Progranulin promotes colorectal cancer proliferation and angiogenesis through TNFR2/Akt and ERK signaling pathways. Am J Cancer Res 5:3085–3097
Koo DH, Park CY, Lee ES, Ro J, Oh SW (2012) Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. PLoS ONE 7:e39880
Han JJ, Yu M, Houston N, Steinberg SM, Kohn EC (2011) Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol Oncol 120:5–10
Baker M, Mackenzie IR, Pickering-Brown SM et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919
Cruts M, Gijselinck I, van der Zee J et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924
Van Damme P, Van Hoecke A, Lambrechts D et al (2008) Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181:37–41
Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G (2008) Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71:1235–1239
Tkaczuk KR, Yue B, Zhan M et al (2011) Increased circulating level of the survival factor GP88 (Progranulin) in the serum of breast cancer patients when compared to healthy subjects. Breast Cancer (Auckl) 5:155–162
Yamamoto Y, Takemura M, Serrero G et al (2014) Increased serum GP88 (progranulin) concentrations in rheumatoid arthritis. Inflammation 37:1806–1813
Acknowledgements
The authors would like to thank Dr. T. Kudo, Dr. M. Yasunishi, Dr. A. Takekoshi, Dr. N. Harada, Dr. A. Koumura and Dr. M. Yamada (Departments of Neurology and Geriatrics, Gifu University Graduate School of Medicine) for providing patients’ clinical information. We also thank Marla Brunker, from Edanz Group (http://www.edanzediting.com/ac) for editing a draft of this manuscript.
Funding
This research was partially supported by a Grant-in-Aid for Scientific Research (C) (26461290) from the Japan Society for the Promotion of Science.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
11060_2017_2742_MOESM1_ESM.tif
Supplementary Figure 1—Brain MRI of a patient with CNS+ lymphoma, whose CSF PGRN value exceeds the cutoff level, despite having normal brain MRI and CSF findings. FLAIR (A) and enhanced T1-weighted (B) images after one month of confirming increased CSF PGRN level (5.33 ng/mL) show no abnormal findings. FLAIR (C) and enhanced T1-weighted (D) images two months later show extended white matter hyperintensities and multiple parenchymal and leptomeningeal enhancement lesions. CNS: central nervous system, CSF: cerebrospinal fluid, FLAIR: fluid attenuated inversion recovery, MRI: magnetic resonance imaging, PGRN: progranulin (TIF 7076 KB)
11060_2017_2742_MOESM2_ESM.tif
Supplementary Figure 2—FLAIR images of a patient with CNS+ lymphoma, whose CSF PGRN levels increased with getting worse of brain MRI findings. (A, B) FLAIR images when CSF PGRN level was 3.18 ng/mL Slight hyperintensity lesions were observed in bilateral internal capsule and pontine tegmentum. (C, D) FLAIR images in the same patient four months later, when CSF PGRN level was 24.65 ng/mL Extended hyperintensity lesions were observed in cerebral white matter, brain stem, and cerebellum. CNS: central nervous system, CSF: cerebrospinal fluid, FLAIR: fluid attenuated inversion recovery, MRI: magnetic resonance imaging, PGRN: progranulin (TIF 7522 KB)
Rights and permissions
About this article
Cite this article
Kimura, A., Takemura, M., Serrero, G. et al. Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis. J Neurooncol 137, 455–462 (2018). https://doi.org/10.1007/s11060-017-2742-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-017-2742-z